Who would be the winner? A prognostic nomogram for predicting the benefit of postoperative radiotherapy ± chemotherapy in patients with locally advanced gastric cancer: TROD-02-01 study
Open Access
- 4 March 2024
- journal article
- research article
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (7) , 3056-3062
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆Annals of Oncology, 2021
- Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trialThe Lancet Oncology, 2018
- Precision medicine in the adjuvant treatment of gastric cancerThe Lancet Oncology, 2018
- Changing Trends in Stomach Cancer Throughout the WorldCurrent Gastroenterology Reports, 2017
- Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric CancerJAMA Surgery, 2017
- Gastric cancerThe Lancet, 2016
- Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational studyJournal of Cancer Research and Clinical Oncology, 2014
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trialThe Lancet, 2012
- The impact of total retrieved lymph nodes on staging and survival of patients with pT3 gastric cancerCancer, 2007
- Assessing time‐by‐covariate interactions in proportional hazards regression models using cubic spline functionsStatistics in Medicine, 1994